Wegovy and Mounjaro are two injectable prescription drugs used to lower blood sugar and A1c levels (a measure of blood sugar control over the past two to three months) and aid in weight loss.
This guide will help you decide whether Wegovy or Mounjaro is right for you.
What is the active ingredient in Wegovy vs. Mounjaro?
The active ingredient in Wegovy is semaglutide, and the active ingredient in Mounjaro is tirzepatide. Their mechanism of action is slightly different.
Semaglutide mimics the glucose-like peptide (GLP)-1 hormone in the body, helping to reduce appetite, slow stomach emptying, reduce glucose release from the liver, and increase insulin release.
Tirzepatide has a dual function. It mimics both the GLP-1 and GIP incretin hormones.
It shares the effects of GLP-1, but the addition of GIP action enhances insulin release in response to hyperglycemia and plays a role in fat metabolism. This increases your ability to regulate your appetite and prevent overeating.
Although Wegovy and Mounjaro are similar drugs, they cannot be combined or used at the same time.
Why do people choose Wegovy or Mounjaro?
Wegovy is FDA approved to treat obesity and aid in weight loss.
It is approved for use in people with a body mass index (BMI, a measure of weight relative to height) of 30 or higher, or a BMI of 27 or higher and one or more weight-related conditions (such as type 2 diabetes, high blood pressure, or high cholesterol).
Adolescents 12 years and older with a BMI at or above the 95th percentile for their age and gender are also approved to take Wegovy.
Munjaro is FDA-approved as a treatment to help manage blood sugar levels in adults with type 2 diabetes.
Both are liquid, injectable medications that help lower blood sugar and A1c levels. The sample is taken subcutaneously (just under the skin) in areas such as the abdomen, thighs, and upper arms.
One of these drugs may be prescribed for people who suffer from insulin resistance or weight gain. This is because, in addition to managing blood sugar levels, it slows digestion and suppresses appetite.
Finally, both Wegovy and Mounjaro reduce the risk of heart attack and stroke.
How are Wegovy and Mounjaro similar?
The effects of both drugs are:
Lower blood sugar and A1c levels
Both have been shown to lower blood sugar and A1c levels.
People who take the highest dose of Munjaro (15 milligrams (mg) per week) lower their A1c by an average of 2.3 percent.
The STEP 2 study investigated Wegovy’s effects on blood sugar and A1c levels in patients with type 2 diabetes.
Researchers found that participants who took the drug not only lost weight, but also had statistically significant improvements in their blood sugar and A1c levels.
These drugs do this by increasing insulin secretion.
This action stops the liver from releasing glucose into the bloodstream, increasing insulin sensitivity and helping to prevent hypoglycemia.
may cause weight loss
In studies, both drugs cause weight loss in participants by suppressing appetite and inhibiting the release of glucose from the liver.
In one study, adult participants who took Wegovy lost an average of 15% from their starting weight.
Another study found that adolescents who took Wegovy lost an average of 16% of their starting body weight.
Munjaro can also help with weight loss, but it is not approved by the FDA as a standalone weight loss drug. However, the FDA has approved a drug called Zepbound for this purpose.
Zepbound is chemically identical to Mounjaro and contains the same active ingredients in the same strength, but is sold under a different name when used for weight loss treatment.
In studies, Munjaro helped people lose 12 to 15 pounds at 5 mg per week, 15 to 21 pounds at 10 mg per week, and 17 to 25 pounds at 15 mg per week.
These drugs are not approved by the FDA for use in weight loss, so there is no recommended dosage to take for weight loss.
(For Zepbound, a reduced version of Mounjaro, available doses are 2.5 mg, 5 mg, 10 mg, and 15 mg, taken as a weekly injection. The maximum dose is 15 mg.)
If you are interested in losing weight, talk to your doctor. They will be able to provide useful information on both pharmaceutical and lifestyle approaches.
protect heart health
Both of these drugs lower the risk of heart disease, which is important for people living with diabetes.
In the study, participants who took the highest dose of Munjaro (15 mg per week) had the following results after 52 weeks:
- Reduced total cholesterol by approximately 5.6%
- Triglycerides decreased by 22.5%
- Lowered LDL (“bad”) cholesterol by 7.9 percent
- Reduced VLDL cholesterol by 21.8%
- HDL (“good”) cholesterol increased by 10.8 percent
Additionally, meta-analysis (analysis of data from several clinical trials) lancet We found that GLP-1 receptor agonists, including semaglutide (the active ingredient in Wegovy), reduce cardiovascular risk.
It also reduced the risk of death in people with diabetes and heart disease.
The American Diabetes Association (ADA) recommends GLP-1 agonists for people with type 2 diabetes or heart disease to lower the risk of heart attack and stroke.
In addition to medications, eating a healthy diet and increasing the amount of physical activity you do on a daily basis can go a long way in improving your heart health.
May cause harmful side effects
Taking either of these drugs causes similar side effects.
Both can cause nausea, vomiting, diarrhea, constipation, appetite suppression, and hypoglycemia (if you are taking insulin).
When you first start taking a drug, side effects can be more severe until your body gets used to it.
Tell your doctor if you experience any debilitating side effects that negatively affect your quality of life.
You may be able to reduce your dose or find an alternative medication.
See below for more information. Wegovy side effects: what you need to know and Munjaro side effects: what you need to know.
Not a replacement for insulin
These drugs lower blood sugar levels but do not replace the need for insulin.
Over time, they may reduce the amount of insulin needed, but they are not insulin or a replacement for insulin.
If you experience frequent hypoglycemia, consult your doctor.
It helps you readjust your insulin dosage so you experience fewer drops.
taken once a week
Unlike other GLP-1 drugs such as Victoza, both Wigovy and Munjaro are taken only once a week.
Do not take more than one dose within a week.
Can be taken with or without food
These drugs do not cause acute hypoglycemia and can be taken with or without food.
The important thing is to take it on the same day each week (ideally around the same time so you always remember to take it).
In some cases, people combine taking their medication with a meal, such as breakfast, but this is not necessary.
If you experience severe nausea right after taking the medicine, you may want to eat something bland, such as oatmeal or toast.
May cause changes in vision
These drugs can cause or worsen diabetic retinopathy, especially when taken for the first time.
Studies have shown that semaglutide (the active ingredient in Wegovy) is associated with early worsening of diabetic retinopathy.
Similarly, Mounjaro’s active ingredient (tirzepatide) can worsen diabetic retinopathy.
Although this side effect does not occur in everyone who takes these drugs, this drug does have an increased risk of vision changes or vision worsening.
Consult your doctor if you have early-stage diabetic retinopathy or are concerned that taking Wegovy or Mounjaro may affect your eye health.
What is the difference between Wegovy and Mounjaro?
Wegovy and Moujaro are very similar but different drugs.
The differences between these drugs are:
Dosage varies
Wegovy dosages are:
- For those who are new to treatment: 0.25 mg once weekly for the first 4 weeks.
- Ongoing treatment: 0.5 mg once a week starting from week 5. Pen doses of 1 mg, 1.7 mg, and 2.4 mg are available if your doctor determines you need a larger amount.
read more: Wegovy Dosage Guide: How Much Should I Take?
The dosage of Munjaro is as follows:
- For those who are new to treatment: 2.5 mg once weekly for the first 4 weeks.
- Ongoing treatment: 5 mg once a week starting from week 5. Pen doses of 7.5 mg, 10 mg, 12.5 mg, and 15 mg are available if your doctor determines you need more. These drugs are not interchangeable because their active ingredients are different.
read more: Munjaro Dosage Guide: How Much Should I Take?
Due to the different active ingredients, these doses are not interchangeable and can be very dangerous if you try to use them in this way.
Each contains different active ingredients
Wegovy’s active ingredient is semaglutide (same as Ozempic), and Mounjaro’s active ingredient is tirzepatide.
If you are allergic to either active ingredient, ask your doctor to prescribe an alternative.
Approved by the FDA for a variety of reasons
Wegovy is intended for use as a weight loss and/or weight maintenance drug. It is not an approved drug to treat type 2 diabetes.
However, many people who take Wegovy for weight loss or weight maintenance may also experience improved blood sugar levels from taking the drug.
Mounjaro, on the other hand, is an FDA-approved drug for managing blood sugar levels in patients with type 2 diabetes.
Although it is not approved by the FDA as a weight loss drug, it can also help you lose weight. (As mentioned above, a version of the drug known as Zepbound is approved by the FDA for weight loss.)
Many type 2 diabetics also struggle with weight, so consuming Munjaro to improve blood sugar control can also help with weight loss.
Can I switch between the two medications?
In some cases, yes.
This may be possible, as long as you are not allergic to the ingredients of other medicines.
If you are experiencing severe side effects from one drug, you may want to try another drug to see if your body adapts to it.
If you both meet the eligibility criteria for these two drugs, you are likely able to switch between them. namely obesity and type 2 diabetes.
If you only have type 2 diabetes, your insurance may only cover Munjaro.
Alternatively, if you are obese but do not have type 2 diabetes, you may only qualify for Wegovy.
Switch medications only under your doctor’s guidance.
The dosages of the two drugs are completely different, and overdosing on these drugs can cause serious side effects.
These side effects include nausea, vomiting, and low blood sugar levels, which can be fatal if not treated promptly.
If I lose enough weight on Wegovy or Mounjaro, can I stop taking my other diabetes medications?
This may be possible, but unlikely.
Losing weight can help improve both insulin resistance and blood sugar levels. This may eliminate the need for insulin or other diabetes medications.
However, neither Wigobee nor Munjaro can cure diabetes.
If you have lost a lot of weight and your blood sugar levels are well controlled, you may be able to reduce your insulin needs or stop taking insulin altogether.
This only applies to people with type 2 diabetes, as people with type 1 diabetes must take insulin for the rest of their lives.
If you have questions about taking other diabetes medications while using Wegovy or Mounjaro, ask your doctor.
Is Wegoby better than Munjaro?
Individuals respond differently to these drugs, and what works well for one person may not work well for another.
Additionally, they are approved for different purposes, making it difficult to directly compare their effectiveness.
When it comes to weight loss alone, recent studies suggest that people who take Mounjaro’s active ingredients are more likely to lose 5, 10, or 15 percent of their body weight and experience greater weight loss after 3, 6, and 12 months than those who take Wegovy’s active ingredients.
How much does Wegovy and Mounjaro cost?
Wegovy and Mounjaro costs vary depending on insurance coverage and specific plan details.
To determine your specific copayments or copayments, refer to your prescription or medical card and use Wegovy or Mounjaro’s coverage and copay calculator.
If you have any questions about Wegovy coverage or copays, please contact Novo Nordisk Customer Support at 1-888-693-4883. For Mounjaro, Eli Lilly offers customer support at 1-800-545-5979.
Both Novo Nordisk and Eli Lilly offer Patient Assistance Programs (PAPs) that can provide free medications to qualifying patients.
To learn more about these programs and to see if you qualify, contact Novo Nordisk PAP toll-free at 1-866-310-7549 or Eli Lilly PAP at 1-800-545-6962.
Was this article helpful? Let us know by clicking Yes or No below.
